Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program

Authors:

Abstract
No abstract available
Funding Information
  • F. Hoffmann-La Roche

This publication has 13 references indexed in Scilit: